𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies

✍ Scribed by Laura Q. M. Chow; Daniel L. Gustafson; Cindy L. O’Bryant; Lia Gore; Michele Basche; Scott N. Holden; Mark C. Morrow; Stacy Grolnic; Brian R. Creese; Kaye L. Roberts; Kat Davis; Russell Addison; S. Gail Eckhardt

Publisher
Springer
Year
2008
Tongue
English
Weight
425 KB
Volume
63
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I dose and sequencing study of peg
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies
✍ Paula M. Fracasso; Luis C. Rodriguez; Thomas J. Herzog; Carole L. Fears; Sherry 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad

Phase I trial of weekly docetaxel and ge
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies
✍ Tarek Mekhail; Thomas E. Hutson; Paul Elson; G. Thomas Budd; Gordon Srkalovic; T 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract ## BACKGROUND A Phase I study using weekly docetaxel and gemcitabine was conducted to investigate toxicity; to determine the maximum tolerated dose (MTD) of each agent; and, in a preliminary fashion, to determine the antitumor activity of the combination. ## METHODS Docetaxel and gem